SESAME SEED is a Percutaneous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Allergy Laboratories, Inc.. The primary component is Sesame Seed.
Product ID | 54575-457_dbe7bebd-e445-4e59-8302-e706b795fbde |
NDC | 54575-457 |
Product Type | Human Prescription Drug |
Proprietary Name | SESAME SEED |
Generic Name | Sesame Seed |
Dosage Form | Injection, Solution |
Route of Administration | PERCUTANEOUS; SUBCUTANEOUS |
Marketing Start Date | 1972-08-29 |
Marketing Category | BLA / BLA |
Application Number | BLA102192 |
Labeler Name | Allergy Laboratories, Inc. |
Substance Name | SESAME SEED |
Active Ingredient Strength | 1 g/20mL |
Pharm Classes | Non-Standardized Food Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Allergens [CS],Dietary Proteins [CS],Seed Storage Proteins [CS],Plant Proteins [CS] |
NDC Exclude Flag | E |
Listing Certified Through | 2018-12-31 |
Marketing Start Date | 1972-08-29 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA102192 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 1972-08-29 |
Inactivation Date | 2020-01-31 |
Marketing Category | BLA |
Application Number | BLA102192 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 1972-08-29 |
Inactivation Date | 2020-01-31 |
Marketing Category | BLA |
Application Number | BLA102192 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 1972-08-29 |
Inactivation Date | 2020-01-31 |
Marketing Category | BLA |
Application Number | BLA102192 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 1972-08-29 |
Inactivation Date | 2020-01-31 |
Ingredient | Strength |
---|---|
SESAME SEED | 1 g/20mL |
NDC | Brand Name | Generic Name |
---|---|---|
0268-6213 | SESAME SEED | SESAME SEED |
22840-5748 | Sesame Seed | Sesamum indicum |
49288-0475 | Sesame Seed | Sesame Seed |
54575-457 | SESAME SEED | sesame seed |
70567-020 | Pibubab gold Grain Pack | SESAME SEED |